Literature DB >> 25979957

Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis.

Catherine E Najem1, Rajwardhan Yadav2, Elise Carlson2.   

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare eosinophil-rich disorder characterised by necrotising granulomatous inflammation affecting small to medium sized vessels. Extrapulmonary manifestations can be life-threatening when heart, central nervous system (CNS), gastrointestinal tract or kidneys are affected. We describe a case of a 56-year-old woman with a long-standing history of asthma, who presented with an acute sudden painless loss of vision after she had been recently diagnosed with EGPA and induced with pulse steroids and cyclophosphamide. The patient had a complicated hospital course with multisystemic involvement of active vasculitis, involving heart, kidneys, muscles, eyes and CNS. The patient's devastating condition responded remarkably to Rituximab. The role of Rituximab in EGPA is not yet proven. Few cases are reported in the literature about the role of Rituximab in EGPA, of which only one described retinal artery occlusion as a presentation of a recently treated patient with EGPA. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979957      PMCID: PMC4434326          DOI: 10.1136/bcr-2014-206421

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Authors:  Rachel B Jones; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Dorothy Walsh; Michael Walsh; Kerstin Westman; David R W Jayne
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

3.  Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome.

Authors:  V V Kaushik; H V Reddy; R C Bucknall
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

4.  Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis.

Authors:  Dario Roccatello; Savino Sciascia; Daniela Rossi; Mirella Alpa; Carla Naretto; Alessandra Russo; Elisa Menegatti; Simone Baldovino
Journal:  Am J Nephrol       Date:  2011-07-08       Impact factor: 3.754

5.  Rituximab in Churg-Strauss syndrome.

Authors:  M Koukoulaki; K G C Smith; D R W Jayne
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

6.  Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production.

Authors:  R J Pepper; M A Fabre; C Pavesio; G Gaskin; R B Jones; D Jayne; C D Pusey; A D Salama
Journal:  Rheumatology (Oxford)       Date:  2008-05-20       Impact factor: 7.580

7.  Churg-Strauss syndrome successfully treated with rituximab.

Authors:  Kristin Kveim Dønvik; Roald Omdal
Journal:  Rheumatol Int       Date:  2009-09-30       Impact factor: 2.631

Review 8.  Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis.

Authors:  Renato A Sinico; Luca Di Toma; Antonella Radice
Journal:  Autoimmun Rev       Date:  2012-08-16       Impact factor: 9.754

9.  Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.

Authors:  Natsuka Umezawa; Hitoshi Kohsaka; Toshihiro Nanki; Kaori Watanabe; Michi Tanaka; Peter Y Shane; Nobuyuki Miyasaka
Journal:  Mod Rheumatol       Date:  2014-02-11       Impact factor: 3.023

10.  Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  Jens Thiel; Fabian Hässler; Ulrich Salzer; Reinhard E Voll; Nils Venhoff
Journal:  Arthritis Res Ther       Date:  2013-09-24       Impact factor: 5.156

View more
  2 in total

Review 1.  Retinal vasculitis.

Authors:  James T Rosenbaum; Cailin H Sibley; Phoebe Lin
Journal:  Curr Opin Rheumatol       Date:  2016-05       Impact factor: 5.006

Review 2.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.